Reviewed listing: NASDAQ:ZVRA · Analysis dated Oct 21, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Zevra develops and sells medicines for rare diseases. Its leading product is MIPLYFFA for Niemann-Pick disease type C. It is approved in the US.
What supports the business?
The core business has improved: in the most recently reported quarter, revenue increased by just over 53 percent, and Zevra earned an operating profit. Cash from operating activities was also higher in the first half as a whole than cash used.
What could improve?
Treating more patients in the United States could increase earnings. A later European approval and successful new drugs would be additional opportunities. Neither is a secured value today.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
10.47 USD are reasonable under certain conditions, but are not an obvious bargain. My midrange estimate is about 10 USD. To justify substantially more value, Zevra would need to keep increasing cash flow; a weak trajectory could be worth significantly less.
What is the main risk?
Almost the entire business depends on the active ingredient arimoclomol. The European authority questions the persuasiveness of the efficacy data; a re-examination is under way. Reimbursement, competition, and new equity rights may weigh on earnings per share.
What is the overall assessment?
Zevra is selling significantly more of its leading drug and is now generating positive cash flow. 10.47 USD are reasonable if business success continues, but in my midrange calculation they offer little margin of safety. Strong product dependence and the unresolved European approval process argue for a watch rating.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · www.sec.gov · Aug 05, 2026
- Original source 2 · investors.zevra.com · Mar 09, 2026
- Original source 3 · investors.zevra.com · Aug 05, 2026
- Original source 4 · www.ema.europa.eu · Jul 24, 2026
- Original source 5 · www.ema.europa.eu · Oct 12, 2026
- Original source 6 · investors.zevra.com · Oct 20, 2026
- Original source 7 · investors.zevra.com · Aug 21, 2026
- Original source 8 · api-v4.fcsapi.com